Free tool
FAERS Monitor: Invega Sustenna
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022264 or its brand name (Invega Sustenna, Paliperidone Palmitate). Reports on generic versions are filed under their own applications.
Reports
28,106
Serious
12,195
43% of reports
Hospitalization
5,908
Death reported
1,104
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use3,059
- drug ineffective1,783
- hospitalisation1,667
- weight increased1,601
- drug dose omission1,339
- product dose omission issue1,153
- gynaecomastia1,065
- schizophrenia897
- treatment noncompliance891
- blood prolactin increased855
- incorrect dose administered806
- psychotic disorder740
- inappropriate schedule of drug administration739
- condition aggravated717
- galactorrhoea657
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 26 |
| 2010 | 640 |
| 2011 | 1,000 |
| 2012 | 1,510 |
| 2013 | 1,560 |
| 2014 | 1,509 |
| 2015 | 1,658 |
| 2016 | 1,579 |
| 2017 | 2,433 |
| 2018 | 1,719 |
| 2019 | 1,689 |
| 2020 | 1,509 |
| 2021 | 1,601 |
| 2022 | 2,388 |
| 2023 | 1,904 |
| 2024 | 1,855 |
| 2025 | 1,839 |
| 2026 | 1,683 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,026,053 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood prolactin increasedSignal | 855 | 165.5 | 153.8 | 114,359 |
| galactorrhoeaSignal | 657 | 85.1 | 78.6 | 48,987 |
| schizophreniaSignal | 897 | 59.6 | 55.7 | 47,814 |
| gynaecomastiaSignal | 1,065 | 26.6 | 25.1 | 25,394 |
| psychotic disorderSignal | 740 | 19.2 | 17.9 | 12,455 |
| treatment noncomplianceSignal | 891 | 12.4 | 11.6 | 9,175 |
| hospitalisationSignal | 1,667 | 8.2 | 7.8 | 10,489 |
| inappropriate schedule of drug administrationSignal | 739 | 7.8 | 7.3 | 4,376 |
| drug dose omissionSignal | 1,339 | 6.1 | 5.8 | 5,707 |
| weight increasedSignal | 1,601 | 5.4 | 5.1 | 5,727 |
| product dose omission issueSignal | 1,153 | 2.9 | 2.8 | 1,491 |
| incorrect dose administeredSignal | 806 | 2.6 | 2.5 | 831 |
| off label useSignal | 3,059 | 2.6 | 2.5 | 3,184 |
| condition aggravated | 717 | 1.8 | 1.6 | 241 |
| drug ineffective | 1,783 | 1.0 | 1.0 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.